Radioactivity of biological samples of patients treated with 90Y-DOTATOC
0
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Dosimetric studies in Nuclear Medicine are very important, especially with new therapeutic methods, the number of which has increased significantly with the Theranostic approach (determining diagnostictherapeutic pairs where similar molecules are labelled with different isotopes in order to diagnose and treat malignant diseases). Peptide receptor radionuclide therapy (PRRT) has been used successfully for many years to treat neuroendocrine tumors (NET). 90Y-DOTATOC is one of the radiopharmaceuticals used frequently in this type of therapy. In this work, blood and urine samples from 13 patients treated with 90Y-DOTATOC were measured by a liquid scintillation beta counter (LSC). Calibration of the beta counter for this type of measurement was done and all results are presented in the paper. The presented paper also provides a methodology for determining the measurement uncertainty for this type of measurement. Immediately after the administration of radiopharmaceuticals, the activity in the blood was different from 6.31% to 88.9% of the applied radioactivity, while 3 h after the termination of the application, the average value of radiopharmaceuticals in the blood was only 3.84%. The activity in the excreted urine depended on the time when the patients urinated after the therapy. It was measured that as much as 58% of the applied radioactivity was excreted in the first urine after the therapy in a patient who urinated 4.5 h after the completed application of the therapy. In most patients, the highest urine activity was in the first 10 h after the application, while the activities after that time were negligibly low. The described methodology of measuring and evaluating activity in blood and excreted urine can be applied to other radiopharmaceuticals used in nuclear medicine. It could be useful for researchers for dosimetric assessments in clinical application of PRRT
Abstract
Dosimetric studies in Nuclear Medicine are very important, especially with new therapeutic methods, the number of which has increased significantly with the Theranostic approach (determining diagnostictherapeutic pairs where similar molecules are labelled with different isotopes in order to diagnose and treat malignant diseases). Peptide receptor radionuclide therapy (PRRT) has been used successfully for many years to treat neuroendocrine tumors (NET). 90Y-DOTATOC is one of the radiopharmaceuticals used frequently in this type of therapy. In this work, blood and urine samples from 13 patients treated with 90Y-DOTATOC were measured by a liquid scintillation beta counter (LSC). Calibration of the beta counter for this type of measurement was done and all results are presented in the paper. The presented paper also provides a methodology for determining the measurement uncertainty for this type of measurement. Immediately after the administration of radiopharmaceuticals, the activity in the blood was different from 6.31% to 88.9% of the applied radioactivity, while 3 h after the termination of the application, the average value of radiopharmaceuticals in the blood was only 3.84%. The activity in the excreted urine depended on the time when the patients urinated after the therapy. It was measured that as much as 58% of the applied radioactivity was excreted in the first urine after the therapy in a patient who urinated 4.5 h after the completed application of the therapy. In most patients, the highest urine activity was in the first 10 h after the application, while the activities after that time were negligibly low. The described methodology of measuring and evaluating activity in blood and excreted urine can be applied to other radiopharmaceuticals used in nuclear medicine. It could be useful for researchers for dosimetric assessments in clinical application of PRRT
참고문헌 (29)
- A.J. Craig, "Comparison of 90Y SIRT predicted and delivered absorbed doses using a PSF conversion method", Phys. Med, 89, pp.1~10 (2021)
- M. Elschot, "Quantitative comparison of PET and Bremsstrahlung SPECT for imaging the in vivo yttrium-90 microsphere distribution after liver radioembolization", PLoS One, 8(2), pp.e55742~ (2013)
- Y. K. Dewaraja, "Improved quantitative 90Y bremsstrahlung SPECT", CT reconstruction with Monte Carlo scatter modeling, 2017, pp.44(12), 6364~6376
- M. Elschot, "Quantitative evaluation of scintillation camera imaging characteristics of isotopes used in liver radioembolization", PLoS One, 6(11), pp.e26174~ (2011)
- L. P. Clarke, "Bremsstrahlung imaging using the gamma-camera-factors affecting attenuation", J. Nucl. Med, 33(1), pp.161~166 (1992)
- S. Ito, "Y-90bremsstrahlung emission computed tomography using gamma cameras", Ann. Nucl. Med, 23(3), pp.257~267 (2009)
- Y. Menda, "90Y-DOTATOC dosimetry-based personalized peptide receptor radionuclide therapy", J. Nucl. Med, 59(11), pp.1692~1698 (2018)
- M. T. Madsen, "Personalized Kidney Dosimetry for Y-90 DOTATOC Radionuclide Therapy", SNMMI's 63rd Annual Meeting (2016)
- R. Baum, "THERANOSTICS: from molecular imaging using Ga-68labeled tracers and PET", CT to personalized radionuclide therapyethe bad berka experience, 2012, pp.2(5), 437~447
- J. B. Cwikla, "Efficacy of radionuclide treatment DOTATATE Y-90in patients with progressive metastatic gastroenteropancreatic neuroendocrine carcinomas (GEP-NETs): a phase II study", Ann. Oncol, 21(4), pp.787~794 (2010)
- "Bergsma H. PRRT & Onkology Erasmus University Rotterdam", 1~260 (2017)
- R. Barone, "Patient-specific dosimetry in predicting renal toxity with (90)Y-DOTATOC:relevance of kidney volume and dose rate finding a dose-effect relationship", J. Nucl. Med, 46(1), pp.99S~106S (2005)
- F. Jamar, "86YDOTA0-d-Phe1-Tyr3-octreotide (SMT487) - a phase 1 clinical study: pharmacokinetics, biodistribution and renal protective effect of different regimens of amino acid co-infusion", EJNMMI, 30(4), pp.510~518 (2003)
- octreotide: the Rotterdam experience, "Semin. Nucl. Med", 2002, 110~122
- S. Walrand, "Experimental facts supporting a red marrow uptake due to radiometal transchelation in 90Y-DOTATOC therapy and relationship to the decrease of platelet counts", EJNMMI, 38(7), pp.1270~1280 (2011)
- "International Commission on Radiological Protection ICRP 140, Radiological Protection in Therapy with Radiopharmaceuticals, ICRP Publication 140", SAGE Publications Ltd, 1~102 (2019)
- octreotide in patients with advanced gastroenteropancreatic neuroendocrinetumors, "Semin. Nucl. Med", 2006, 147~156
- D. J. Kwekkeboom, "Overview of results of peptide receptor radionuclide therapy with 3 radiolabeled somatostatin analogs", J. Nucl. Med, 46(1), pp.62S~ (2005)
- D. L. Bushnell, "90Y-edotreotide for metastatic carcinoid refractory to octreotide", J. Clin. Oncol, 28(10), pp.1652~1659 (2010)
- J. Strosberg, "Phase 3 trial of 177Lu-dotatate for midgut neuroendocrine tumors", N. Engl. J. Med, 376(2), pp.125~135 (2017)
- L. Bodei, "Long-term evaluation of renal toxicity after peptide receptor radionuclide therapy with 90Y-DOTATOC and 177Lu-DOTATATE : the role associated factors", EJNMMI, 35(10), pp.1847~1856 (2008)
- R. Dale, "Use of the linear-quadratic radiobiological model for quantifying kidney response in targeted radiotherapy", Cancer Biother. Radiopharm, 19(3), pp.363~370 (2004)
- B. Tenjovic, "90Sr", 90Y determination in milk by Cherenkov radiation after microwave digestion, 2019, pp.320(3), 679~687
- B. B. Sadi, "Emergency radiobioassay method for determination of 90Sr and 226Ra in a spot urine sample", Anal. Chem, 87(15), pp.7931~7937 (2015)
- Octreotate, "NT& RP", 2012, 260~268
- J. Zaknun, "The joint IAEA, EANM, and SNMMI practical guidance on peptide receptor radionuclide therapy (PRRNT) in neuroendocrine tumours", EJNMMI, 40(5), pp.800~816 (2013)
- J. A. Retzlaff, "Erythrocyte volume, plasma volume, and lean body mass in adult men and women", J. Hematol, 33(5), pp.649~661 (1969)
- C. Hindorf, "Dosimetry for 90Y-DOTATOC therapies in patients with neuroendocrine tumors", Cancer Biother. Radiopharm, 22(1), pp.130~135 (2007)
- M. Z. Jeremic, "A fivecompartment biokinetic model for 90Y-DOTATOC therapy", Med. Phys, 45(12), pp.5577~5585 (2018)